Payment overview · 2025
General Payments
$314.55
17 reported records · 8 companies
Healthcare provider profile · identity verified
Benjamin Michael Rogers, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CULLMAN, AL · NPI 1801023502
Verified facts
What the public records show
CMS Open Payments records show Benjamin Michael Rogers, M.D. received $314.55 in general payments during 2025 across 17 reported records.
PFIZER INC. accounted for 17.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.51 | 17.0% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.46 | 15.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.09 | 15.3% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.46 | 14.8% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $44.36 | 14.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.20 | 11.8% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.97 | 6.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.50 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $314.55 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $63.33 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $49.46 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.09 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.09 | 3 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $46.46 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 116 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
116 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
190 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 664 | 239 |
| Levothyroxine Sodium | Levothyroxine Sodium | 399 | 133 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 350 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 325 | 123 |
| Lisinopril | Lisinopril | 307 | 137 |
| Gabapentin | Gabapentin | 289 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 288 | 110 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 237 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 59 |
| Eliquis | Apixaban | 190 | 43 |
| Omeprazole | Omeprazole | 187 | 78 |
| Chlorthalidone | Chlorthalidone | 177 | 64 |
| Montelukast Sodium | Montelukast Sodium | 165 | 63 |
| Famotidine | Famotidine | 142 | 53 |
| Losartan Potassium | Losartan Potassium | 142 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 136 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 48 |
| Ozempic | Semaglutide | 124 | 28 |
| Farxiga | Dapagliflozin Propanediol | 116 | 22 |
| Metformin Hcl Er | Metformin Hcl | 116 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 31 |
| Alendronate Sodium | Alendronate Sodium | 106 | 39 |
| Pregabalin | Pregabalin | 105 | 20 |
| Allopurinol | Allopurinol | 101 | 33 |
| Trulicity | Dulaglutide | 100 | 15 |
| Sertraline Hcl | Sertraline Hcl | 99 | 25 |
| Furosemide | Furosemide | 96 | 45 |
| Potassium Chloride | Potassium Chloride | 85 | 43 |
| Metformin Hcl | Metformin Hcl | 81 | 36 |
| Trazodone Hcl | Trazodone Hcl | 80 | 33 |
| Jardiance | Empagliflozin | 79 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 32 |
| Celecoxib | Celecoxib | 78 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 23 |
| Simvastatin | Simvastatin | 75 | 25 |
| Mounjaro | Tirzepatide | 71 | 19 |
| Tramadol Hcl | Tramadol Hcl | 71 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 21 |
| Buspirone Hcl | Buspirone Hcl | 66 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 29 |
| Meloxicam | Meloxicam | 62 | 22 |
| Spironolactone | Spironolactone | 62 | 24 |
| Benazepril Hcl | Benazepril Hcl | 60 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 54 | 20 |
| Ezetimibe | Ezetimibe | 54 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 20 |
| Xarelto | Rivaroxaban | 52 | 14 |
| Carvedilol | Carvedilol | 51 | 18 |
| Finasteride | Finasteride | 51 | 12 |
| Donepezil Hcl | Donepezil Hcl | 49 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | 18 |
| Warfarin Sodium | Warfarin Sodium | 46 | 13 |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 41 | suppressed |
| Mirtazapine | Mirtazapine | 39 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | 11 |
| Cefdinir | Cefdinir | 32 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | 13 |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Invokana | Canagliflozin | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Prednisone | Prednisone | 27 | 14 |
| Rybelsus | Semaglutide | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Sutab | Sod Sulf/Pot Chloride/Mag Sulf | 23 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | 13 |
| Glipizide | Glipizide | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Methimazole | Methimazole | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Clonazepam | Clonazepam | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $314.55 · 17 records | PFIZER INC. | ABRYSVO, BREZTRI, COMIRNATY, FARXIGA, Kerendia, LEQEMBI, QULIPTA, RECORLEV, TRINTELLIX, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error